FTO-IN-16
FTO-IN-16 (Compound 8a-1), a FTO-IN-15 (HY-179266) prodrug, is a potent FTO inhibitor. FTO-IN-16 suppresses acute myeloid leukemia (AML) cell viability, increases m6A levels, downregulates c-Myc and CEBPA, and upregulates ASB2 and RARA. FTO-IN-16 induces apoptosis. FTO-IN-16 demonstrates strong in vivo efficacy in AML mouse xenografts. FTO-IN-16 can be used for the research of AML.
For research use only. We do not sell to patients.
- Formula: C23H23Cl2N3O6
- Molecular Weight:508.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
FTO-IN-16 (0-8 μM; 48 h) downregulates c-Myc and CEBPA (protein and mRNA), and upregulates ASB2 and RARA in multiple AML cells (NB4, MOLM13, MV4-11, HEL, OCI-AML3, NOMO-1, KG-1)[1].
FTO-IN-16 (0-20 μM; 48 h) induces dose-dependent apoptosis in NB4 cells[1].
FTO-IN-16 (0-8 μM; 48 h) downregulates c-Myc and CEBPA (protein and mRNA), and upregulates ASB2 and RARA in multiple AML cells (NB4, MOLM13, MV4-11, HEL, OCI-AML3, NOMO-1, KG-1)[1].
FTO-IN-16 (72 h) exhibits potent antileukemic activity across a panel of AML cell lines, with IC50 values of 5.5 (NB4), 2.3 (MOLM13), 4.4 (KG-1), 3.6 (MV4-11), 4.6 (HEL), 5.2 (OCI-AML3), and 4.7 μM (NOMO-1), respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MOLM13
-
Concentration:0, 2, 4, 8 μM
-
Incubation Time:24, 48, 72 h
-
Result:Induced time-dependent growth inhibition. Significantly inhibited cell growth after 72 h treatment at 8 μM compared to the control.
-
Cell Line:NB4
-
Concentration:0, 1, 2, 4 μM
-
Incubation Time:7 days
-
Result:Induced dose-dependent suppression of colony formation.
-
Cell Line:NB4
-
Concentration:0, 5, 10, 20 μM
-
Incubation Time:48 h
-
Result:Induced dose-dependent apoptosis.
-
Cell Line:NB4, MOLM13, MV4-11, HEL, OCI-AML3, NOMO-1, KG-1
-
Concentration:0, 2, 4, 8 μM
-
Incubation Time:48 h
-
Result:Upregulated tumor suppressors RARA and ASB2. Reduced protein levels of the oncoproteins CEBPA and c-Myc. The downregulation of c-Myc protein was consistently observed across 7 tested AML cell lines. Did not alter the protein levels of FTO itself or other major m6A regulators, including ALKBH5 and METTL3.
-
Cell Line:NB4
-
Concentration:0, 4, 8 μM
-
Incubation Time:48 h
-
Result:Increased ASB2 expression accompanied by decreased c-Myc and CEBPA transcripts.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice subcutaneously injected with NB4 AML cells[1]
-
Dosage:30 and 60 mg/kg
-
Administration:i.p.; daily for 9 days
-
Result:Significantly suppressed tumor growth in a dose-dependent manner. Showed no significant body weight loss or organ toxicity. Resulted in upregulation of tumor suppressors (RARA, ASB2) and downregulation of oncoproteins (CEBPA, c-Myc). Showed a marked increase in global RNA m6A modifications.
Chemical Information
-
Molecular Weight 508.35
-
Formula C23H23Cl2N3O6
-
SMILES
O=C(C1=CC=CC=C1NC2=C(C=C(C=C2Cl)C(NCCNC(/C=C/C(OCC)=O)=O)=O)Cl)OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz